{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,15]],"date-time":"2026-11-15T02:45:14Z","timestamp":1794710714771,"version":"4.9.1"},"reference-count":139,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Urology"],"published-print":{"date-parts":[[2025,6]]},"DOI":"10.1016\/j.eururo.2025.02.020","type":"journal-article","created":{"date-parts":[[2025,3,20]],"date-time":"2025-03-20T05:11:17Z","timestamp":1742447477000},"page":"683-696","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":405,"title":["European Association of Urology Guidelines on Renal Cell Carcinoma: The 2025 Update"],"prefix":"10.1016","volume":"87","author":[{"given":"Axel","family":"Bex","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasmin Abu","family":"Ghanem","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurence","family":"Albiges","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephanie","family":"Bonn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Riccardo","family":"Campi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Umberto","family":"Capitanio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saeed","family":"Dabestani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Milan","family":"Hora","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tobias","family":"Klatte","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Teele","family":"Kuusk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lars","family":"Lund","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lorenzo","family":"Marconi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlotta","family":"Palumbo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Geraldine","family":"Pignot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Powles","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natasha","family":"Schouten","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maxine","family":"Tran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandro","family":"Volpe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jens","family":"Bedke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.eururo.2025.02.020_b0005","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1159\/000049783","article-title":"Guidelines on renal cell cancer","volume":"40","author":"Mickisch","year":"2001","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2025.02.020_b0010","series-title":"EAU guidelines on renal cell carcinoma: the 2025 update","author":"Bex","year":"2025"},{"key":"10.1016\/j.eururo.2025.02.020_b0015","unstructured":"Phillips B. Oxford Centre for Evidence-based Medicine: levels of evidence (March 2009). https:\/\/www.cebm.ox.ac.uk\/resources\/levels-of-evidence\/oxford-centre-for-evidence-based-medicine-levels-of-evidence-march-2009."},{"key":"10.1016\/j.eururo.2025.02.020_b0020","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1136\/bmj.39493.646875.AE","article-title":"Going from evidence to recommendations","volume":"336","author":"Guyatt","year":"2008","journal-title":"BMJ"},{"key":"10.1016\/j.eururo.2025.02.020_b0025","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1016\/j.ejca.2018.07.005","article-title":"Cancer incidence and mortality patterns in Europe: estimates for 40 countries and 25 major cancers in 2018","volume":"103","author":"Ferlay","year":"2018","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.eururo.2025.02.020_b0030","doi-asserted-by":"crossref","first-page":"229","DOI":"10.3322\/caac.21834","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.eururo.2025.02.020_b0035","series-title":"Global Cancer Observatory: cancer today (version 1.1)","author":"Ferlay","year":"2024"},{"key":"10.1016\/j.eururo.2025.02.020_b0040","doi-asserted-by":"crossref","first-page":"231","DOI":"10.3109\/21681805.2013.864698","article-title":"Tumour characteristics and surgical treatment of renal cell carcinoma in Sweden 2005\u20132010: a population-based study from the national Swedish kidney cancer register","volume":"48","author":"Thorstenson","year":"2014","journal-title":"Scand J Urol"},{"key":"10.1016\/j.eururo.2025.02.020_b0045","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.eururo.2016.02.029","article-title":"The 2016 WHO classification of tumours of the urinary system and male genital organs\u2014part A: renal, penile, and testicular tumours","volume":"70","author":"Moch","year":"2016","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2025.02.020_b0050","series-title":"Cancer today","author":"World Health Organization","year":"2024"},{"key":"10.1016\/j.eururo.2025.02.020_b0055","unstructured":"European Commission. ECIS: European cancer information system. https:\/\/ecis.jrc.ec.europa.eu\/."},{"key":"10.1016\/j.eururo.2025.02.020_b0060","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1093\/ndt\/gfae036","article-title":"Global epidemiology of kidney cancer","volume":"39","author":"Cirillo","year":"2024","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.eururo.2025.02.020_b0065","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.eururo.2018.08.036","article-title":"Epidemiology of renal cell carcinoma","volume":"75","author":"Capitanio","year":"2019","journal-title":"Eur Uro."},{"key":"10.1016\/j.eururo.2025.02.020_b0070","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1016\/j.eururo.2022.08.019","article-title":"Epidemiology of renal cell carcinoma: 2022 update","volume":"82","author":"Bukavina","year":"2022","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2025.02.020_b0075","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1097\/MOU.0000000000000454","article-title":"Prevention of kidney cancer incidence and recurrence: lifestyle, medication and nutrition","volume":"28","author":"Tahbaz","year":"2018","journal-title":"Curr Opin Urol"},{"key":"10.1016\/j.eururo.2025.02.020_b0080","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1016\/j.euf.2020.12.020","article-title":"A global trend analysis of kidney cancer incidence and mortality and their associations with smoking, alcohol consumption, and metabolic syndrome","volume":"8","author":"Huang","year":"2022","journal-title":"Eur Urol Focus"},{"key":"10.1016\/j.eururo.2025.02.020_b0085","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2022.928619","article-title":"Association between metabolic syndrome and risk of renal cell cancer: a meta-analysis","volume":"12","author":"Du","year":"2022","journal-title":"Front Oncol"},{"key":"10.1016\/j.eururo.2025.02.020_b0090","first-page":"1317","article-title":"The relationship between blood pressure and risk of renal cell carcinoma","volume":"51","author":"Alcala","year":"2022","journal-title":"Int J Epidemiol"},{"key":"10.1016\/j.eururo.2025.02.020_b0095","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/j.eururo.2022.04.032","article-title":"Obesity in relation to renal cell carcinoma incidence and survival in three prospective studies","volume":"82","author":"Graff","year":"2022","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2025.02.020_b0100","doi-asserted-by":"crossref","first-page":"1406","DOI":"10.1158\/1055-9965.EPI-20-0015","article-title":"Prevalence of cigarette smoking among patients with different histologic types of kidney cancer","volume":"29","author":"Gansler","year":"2020","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"10.1016\/j.eururo.2025.02.020_b0105","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1007\/s00345-022-03993-6","article-title":"Screening programs for renal cell carcinoma: a systematic review by the EAU young academic urologists renal cancer working group","volume":"41","author":"Diana","year":"2023","journal-title":"World J Urol"},{"key":"10.1016\/j.eururo.2025.02.020_b0110","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1007\/s00345-018-2286-7","article-title":"Epidemiology and screening for renal cancer","volume":"36","author":"Rossi","year":"2018","journal-title":"World J Urol"},{"key":"10.1016\/j.eururo.2025.02.020_b0115","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2022-063018","article-title":"The Yorkshire Kidney Screening Trial (YKST): protocol for a feasibility study of adding non-contrast abdominal CT scanning to screen for kidney cancer and other abdominal pathology within a trial of community-based CT screening for lung cancer","volume":"12","author":"Usher-Smith","year":"2022","journal-title":"BMJ Open"},{"key":"10.1016\/j.eururo.2025.02.020_b0120","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1111\/bju.16260","article-title":"Short-term psychosocial outcomes of adding a non-contrast abdominal computed tomography (CT) scan to the thoracic CT within lung cancer screening","volume":"133","author":"Usher-Smith","year":"2024","journal-title":"BJU Int"},{"key":"10.1016\/j.eururo.2025.02.020_b0125","first-page":"132","article-title":"Prognostic impact of paraneoplastic syndromes on patients with non-metastatic renal cell carcinoma undergoing surgery: results from Canadian Kidney Cancer information system","volume":"15","author":"Sun","year":"2021","journal-title":"Can Urol Assoc J"},{"key":"10.1016\/j.eururo.2025.02.020_b0130","doi-asserted-by":"crossref","first-page":"462","DOI":"10.3109\/21681805.2013.777364","article-title":"Incidentally detected renal cell carcinomas are highly associated with comorbidity and mortality unrelated to renal cell carcinoma","volume":"47","author":"Sand","year":"2013","journal-title":"Scand J Urol"},{"key":"10.1016\/j.eururo.2025.02.020_b0135","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2019-035938","article-title":"Challenges of early renal cancer detection: symptom patterns and incidental diagnosis rate in a multicentre prospective UK cohort of patients presenting with suspected renal cancer","volume":"10","author":"Vasudev","year":"2020","journal-title":"BMJ Open"},{"key":"10.1016\/j.eururo.2025.02.020_b0140","doi-asserted-by":"crossref","first-page":"10","DOI":"10.3322\/caac.21871","article-title":"Cancer statistics, 2025","volume":"75","author":"Siegel","year":"2025","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.eururo.2025.02.020_b0145","doi-asserted-by":"crossref","first-page":"e345","DOI":"10.1016\/j.clgc.2018.07.024","article-title":"Imaging in suspected renal-cell carcinoma: systematic review","volume":"17","author":"Vogel","year":"2019","journal-title":"Clin Genitourin Cancer"},{"key":"10.1016\/j.eururo.2025.02.020_b0150","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1016\/S1470-2045(24)00402-9","article-title":"[89Zr]Zr-girentuximab for PET-CT imaging of clear-cell renal cell carcinoma: a prospective, open-label, multicentre, phase 3 trial","volume":"25","author":"Shuch","year":"2024","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.eururo.2025.02.020_b0155","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1111\/bju.15001","article-title":"Chest computed tomography for staging renal tumours: validation and simplification of a risk prediction model from a large contemporary retrospective cohort","volume":"125","author":"Voss","year":"2020","journal-title":"BJU Int"},{"key":"10.1016\/j.eururo.2025.02.020_b0160","doi-asserted-by":"crossref","first-page":"432","DOI":"10.6004\/jnccn.2020.7634","article-title":"Prognosis of incidental brain metastases in patients with advanced renal cell carcinoma","volume":"19","author":"Kotecha","year":"2021","journal-title":"J Natl Compr Cancer Netw"},{"key":"10.1016\/j.eururo.2025.02.020_b0165","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1148\/radiol.2019182646","article-title":"Bosniak classification of cystic renal masses, version 2019: an update proposal and needs assessment","volume":"292","author":"Silverman","year":"2019","journal-title":"Radiology"},{"key":"10.1016\/j.eururo.2025.02.020_b0170","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1016\/j.juro.2017.09.078","article-title":"Natural history of complex renal cysts: clinical evidence supporting active surveillance","volume":"199","author":"Chandrasekar","year":"2018","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2025.02.020_b0175","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.1007\/s00330-022-09102-w","article-title":"Proportion of malignancy in Bosniak classification of cystic renal masses version 2019 (v2019) classes: systematic review and meta-analysis","volume":"33","author":"McGrath","year":"2023","journal-title":"Eur Radiol"},{"key":"10.1016\/j.eururo.2025.02.020_b0180","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1016\/j.eururo.2015.07.072","article-title":"Systematic review and meta-analysis of diagnostic accuracy of percutaneous renal tumour biopsy","volume":"69","author":"Marconi","year":"2016","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2025.02.020_b0185","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1016\/j.eururo.2011.06.021","article-title":"Outcomes of small renal mass needle core biopsy, nondiagnostic percutaneous biopsy, and the role of repeat biopsy","volume":"60","author":"Leveridge","year":"2011","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2025.02.020_b0190","unstructured":"WHO Classification of Tumours Editorial Board. Urinary and male genital tumours. WHO classification of tumors, volume 5. ed 8. Lyon, France: International Agency for Research on Cancer; 2022."},{"key":"10.1016\/j.eururo.2025.02.020_b0195","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1016\/j.eururo.2022.06.016","article-title":"The 2022 World Health Organization classification of tumours of the urinary system and male genital organs\u2014part A: renal, penile, and testicular tumours","volume":"82","author":"Moch","year":"2022","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2025.02.020_b0200","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/j.eururo.2022.11.001","article-title":"European Association of Urology Guidelines Panel on Renal Cell Carcinoma update on the new World Health Organization classification of kidney tumours 2022: the urologist\u2019s point of view","volume":"83","author":"Hora","year":"2023","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2025.02.020_b0205","unstructured":"Bierley JD, Gospodarowicz MK, Wittekind C, editors. TNM classification of malignant tumours. ed 8. Geneva, Switzerland: Union for International Cancer Control; 2016."},{"key":"10.1016\/j.eururo.2025.02.020_b0210","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.eururo.2022.09.026","article-title":"A renewal of the TNM staging system for patients with renal cancer to comply with current decision-making: proposal from the European Association of Urology guidelines panel","volume":"83","author":"Capitanio","year":"2023","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2025.02.020_b0215","doi-asserted-by":"crossref","first-page":"980","DOI":"10.1016\/j.eururo.2015.04.010","article-title":"A literature review of renal surgical anatomy and surgical strategies for partial nephrectomy","volume":"68","author":"Klatte","year":"2015","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2025.02.020_b0220","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.eururo.2015.08.008","article-title":"An arterial based complexity (ABC) scoring system to assess the morbidity profile of partial nephrectomy","volume":"69","author":"Spaliviero","year":"2016","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2025.02.020_b0225","doi-asserted-by":"crossref","first-page":"e13","DOI":"10.1016\/j.clgc.2013.07.009","article-title":"Zonal NePhRO scoring system: a superior renal tumor complexity classification model","volume":"12","author":"Hakky","year":"2014","journal-title":"Clin Genitourin Cancer"},{"issue":"16 Suppl","key":"10.1016\/j.eururo.2025.02.020_b0230","doi-asserted-by":"crossref","first-page":"4506","DOI":"10.1200\/JCO.2024.42.16_suppl.4506","volume":"42","author":"Albiges","year":"2024","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eururo.2025.02.020_b0235","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.euros.2021.12.003","article-title":"Patient-reported experience of diagnosis, management, and burden of renal cell carcinomas: results from a global patient survey in 43 countries","volume":"37","author":"Giles","year":"2022","journal-title":"Eur Urol Open Sci"},{"key":"10.1016\/j.eururo.2025.02.020_b0240","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.1016\/j.eururo.2012.07.028","article-title":"Systematic review of perioperative and quality-of-life outcomes following surgical management of localised renal cancer","volume":"62","author":"MacLennan","year":"2012","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2025.02.020_b0245","article-title":"Partial nephrectomy versus radical nephrectomy for clinical localised renal masses","volume":"2017","author":"Kunath","year":"2017","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.eururo.2025.02.020_b0250","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1016\/j.eururo.2010.12.013","article-title":"A prospective, randomised EORTC intergroup phase 3 study comparing the oncologic outcome of elective nephron-sparing surgery and radical nephrectomy for low-stage renal cell carcinoma","volume":"59","author":"Van Poppel","year":"2011","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2025.02.020_b0255","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1016\/j.eururo.2014.09.027","article-title":"Nephron-sparing techniques independently decrease the risk of cardiovascular events relative to radical nephrectomy in patients with a T1a\u2013T1b renal mass and normal preoperative renal function","volume":"67","author":"Capitanio","year":"2015","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2025.02.020_b0260","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1016\/j.eururo.2011.11.040","article-title":"Comparison of open and minimally invasive partial nephrectomy for renal tumors 4\u20137 centimeters","volume":"61","author":"Sprenkle","year":"2012","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2025.02.020_b0265","doi-asserted-by":"crossref","first-page":"1457","DOI":"10.1111\/j.1464-410X.2011.10597.x","article-title":"Survival after partial and radical nephrectomy for the treatment of stage T1bN0M0 renal cell carcinoma (RCC) in the USA: a propensity scoring approach","volume":"109","author":"Badalato","year":"2012","journal-title":"BJU Int"},{"key":"10.1016\/j.eururo.2025.02.020_b0270","doi-asserted-by":"crossref","first-page":"1170","DOI":"10.21037\/tau-20-1262","article-title":"A meta-analysis for comparison of partial nephrectomy vs. radical nephrectomy in patients with pT3a renal cell carcinoma","volume":"10","author":"Liu","year":"2021","journal-title":"Transl Androl Urol"},{"key":"10.1016\/j.eururo.2025.02.020_b0275","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1016\/j.eururo.2020.10.034","article-title":"Robot-assisted radical nephrectomy: a systematic review and meta-analysis of comparative studies","volume":"80","author":"Crocerossa","year":"2021","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2025.02.020_b0280","doi-asserted-by":"crossref","first-page":"4295","DOI":"10.1007\/s00464-020-07919-4","article-title":"Transperitoneal vs retroperitoneal minimally invasive partial nephrectomy: comparison of perioperative outcomes and functional follow-up in a large multi-institutional cohort (the RECORD 2 project)","volume":"35","author":"Porpiglia","year":"2021","journal-title":"Surg Endosc"},{"key":"10.1016\/j.eururo.2025.02.020_b0285","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.juro.2007.03.038","article-title":"Comparison of 1,800 laparoscopic and open partial nephrectomies for single renal tumors","volume":"178","author":"Gill","year":"2007","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2025.02.020_b0290","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1089\/end.2016.0351","article-title":"Systematic review and meta-analysis of comparative studies reporting perioperative outcomes of robot-assisted partial nephrectomy versus open partial nephrectomy","volume":"31","author":"Xia","year":"2017","journal-title":"J Endourol"},{"key":"10.1016\/j.eururo.2025.02.020_b0295","doi-asserted-by":"crossref","first-page":"4277","DOI":"10.1245\/s10434-016-5411-0","article-title":"Comparison of 1800 robotic and open partial nephrectomies for renal tumors","volume":"23","author":"Peyronnet","year":"2016","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.eururo.2025.02.020_b0300","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1159\/000521881","article-title":"A systematic review and meta-analysis of comparison of outcomes of robot-assisted versus open partial nephrectomy in clinical T1 renal cell carcinoma patients","volume":"106","author":"Ni","year":"2022","journal-title":"Urol Int"},{"key":"10.1016\/j.eururo.2025.02.020_b0305","unstructured":"Grimm MO, Bedke J, Nyarangi-Dix J, et al. Quality of life with open vs robotic-assisted partial nephrectomy (OpeRa) in patients with intermediate\/high-complexity renal tumours. Paper presented at the 38th annual EAU Congress; 10\u201313 March 2023; Milan, Italy. https:\/\/urosource.uroweb.org\/253319\/webcast."},{"key":"10.1016\/j.eururo.2025.02.020_b0310","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.euo.2023.05.011","article-title":"Randomized controlled feasibility trial of robot-assisted versus conventional open partial nephrectomy: the ROBOCOP II study","volume":"7","author":"Kowalewski","year":"2024","journal-title":"Eur Urol Oncol"},{"key":"10.1016\/j.eururo.2025.02.020_b0315","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1177\/0391560319847847","article-title":"On-clamp versus off-clamp robotic partial nephrectomy: a systematic review and meta-analysis","volume":"86","author":"Antonelli","year":"2019","journal-title":"Urologia"},{"key":"10.1016\/j.eururo.2025.02.020_b0320","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1111\/bju.15503","article-title":"Is off-clamp robot-assisted partial nephrectomy beneficial for renal function? Data from the CLOCK trial","volume":"129","author":"Antonelli","year":"2022","journal-title":"BJU Int"},{"key":"10.1016\/j.eururo.2025.02.020_b0325","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1111\/bju.16009","article-title":"Risks and benefits of partial nephrectomy performed with limited or with zero ischaemia time","volume":"132","author":"Cignoli","year":"2023","journal-title":"BJU Int"},{"key":"10.1016\/j.eururo.2025.02.020_b0330","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1016\/j.euo.2023.04.005","article-title":"Off-clamp versus on-clamp robot-assisted partial nephrectomy: a propensity-matched analysis","volume":"6","author":"Sharma","year":"2023","journal-title":"Eur Urol Oncol"},{"key":"10.1016\/j.eururo.2025.02.020_b0335","doi-asserted-by":"crossref","first-page":"2169","DOI":"10.1007\/s00345-022-04016-0","article-title":"Surgical margins after partial nephrectomy as prognostic factor for the risk of local recurrence in pT1 RCC: a systematic review and narrative synthesis","volume":"40","author":"Henderickx","year":"2022","journal-title":"World J Urol"},{"key":"10.1016\/j.eururo.2025.02.020_b0340","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1016\/j.juro.2017.09.072","article-title":"Local tumor bed recurrence following partial nephrectomy in patients with small renal masses","volume":"199","author":"Wood","year":"2018","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2025.02.020_b0345","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1016\/j.eururo.2009.03.048","article-title":"Positive surgical margin appears to have negligible impact on survival of renal cell carcinomas treated by nephron-sparing surgery","volume":"57","author":"Bensalah","year":"2010","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2025.02.020_b0350","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1016\/j.juro.2016.05.078","article-title":"Treatment of patients with positive margins after partial nephrectomy","volume":"196","author":"Kim","year":"2016","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2025.02.020_b0355","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1309\/AJCP7LKLZ8JSJQRG","article-title":"Partial nephrectomy for renal tumors: lack of correlation between margin status and local recurrence","volume":"143","author":"Antic","year":"2015","journal-title":"Am J Clin Pathol"},{"key":"10.1016\/j.eururo.2025.02.020_b0360","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1016\/j.eururo.2013.04.033","article-title":"Systematic review of adrenalectomy and lymph node dissection in locally advanced renal cell carcinoma","volume":"64","author":"Bekema","year":"2013","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2025.02.020_b0365","doi-asserted-by":"crossref","first-page":"1212","DOI":"10.1016\/j.eururo.2011.09.003","article-title":"Lymph node dissection in renal cell carcinoma","volume":"60","author":"Capitanio","year":"2011","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2025.02.020_b0370","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.eururo.2008.09.052","article-title":"Radical nephrectomy with and without lymph-node dissection: final results of European Organization for Research and Treatment of Cancer (EORTC) randomized phase 3 trial 30881","volume":"55","author":"Blom","year":"2009","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2025.02.020_b0375","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1016\/j.juro.2017.11.114","article-title":"Radical nephrectomy with or without lymph node dissection for high risk nonmetastatic renal cell carcinoma: a multi-institutional analysis","volume":"199","author":"Gershman","year":"2018","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2025.02.020_b0380","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.1016\/S0022-5347(05)67699-9","article-title":"Prognostic indicators for renal cell carcinoma: a multivariate analysis of 643 patients using the revised 1997 TNM staging criteria","volume":"163","author":"Tsui","year":"2000","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2025.02.020_b0385","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1111\/bju.14127","article-title":"The role of lymph node dissection in the management of renal cell carcinoma: a systematic review and meta-analysis","volume":"121","author":"Bhindi","year":"2018","journal-title":"BJU Int"},{"key":"10.1016\/j.eururo.2025.02.020_b0390","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1016\/j.eururo.2016.12.027","article-title":"Renal cell carcinoma with isolated lymph node involvement: long-term natural history and predictors of oncologic outcomes following surgical resection","volume":"72","author":"Gershman","year":"2017","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2025.02.020_b0395","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/j.eururo.2015.11.034","article-title":"Systematic review of surgical management of nonmetastatic renal cell carcinoma with vena caval thrombus","volume":"70","author":"Lardas","year":"2016","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2025.02.020_b0400","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1016\/j.eururo.2007.05.009","article-title":"A critical analysis of surgery for kidney cancer with vena cava invasion","volume":"52","author":"Kirkali","year":"2007","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2025.02.020_b0405","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1038\/s41416-022-01883-7","article-title":"A phase II study of neoadjuvant axitinib for reducing the extent of venous tumour thrombus in clear cell renal cell cancer with venous invasion (NAXIVA)","volume":"127","author":"Stewart","year":"2022","journal-title":"Br J Cancer"},{"key":"10.1016\/j.eururo.2025.02.020_b0410","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1259\/bjr\/17514226","article-title":"Pre-operative renal arterial embolisation does not provide survival benefit in patients with radical nephrectomy for renal cell carcinoma","volume":"82","author":"May","year":"2009","journal-title":"Br J Radiol"},{"key":"10.1016\/j.eururo.2025.02.020_b0415","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.eururo.2011.03.030","article-title":"Active surveillance of small renal masses: progression patterns of early stage kidney cancer","volume":"60","author":"Jewett","year":"2011","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2025.02.020_b0420","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1016\/j.eururo.2023.07.012","article-title":"Nephron sparing treatment (NEST) for small renal masses: a feasibility cohort-embedded randomised controlled trial comparing percutaneous cryoablation and robot-assisted partial nephrectomy","volume":"85","author":"Neves","year":"2024","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2025.02.020_b0425","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1016\/j.euo.2020.02.001","article-title":"Limitations of available studies prevent reliable comparison between tumour ablation and partial nephrectomy for patients with localised renal masses: a systematic review from the European Association of Urology Renal Cell Cancer Guideline Panel","volume":"3","author":"Abu-Ghanem","year":"2020","journal-title":"Eur Urol Oncol"},{"key":"10.1016\/j.eururo.2025.02.020_b0430","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1089\/end.2017.0382","article-title":"Renal cell carcinoma: alternative nephron-sparing treatment options for small renal masses, a systematic review","volume":"31","author":"Prins","year":"2017","journal-title":"J Endourol"},{"key":"10.1016\/j.eururo.2025.02.020_b0435","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1007\/s00261-020-02613-4","article-title":"Renal biopsies performed before versus during ablation of T1 renal tumors: implications for prevention of overtreatment and follow-up","volume":"46","author":"Widdershoven","year":"2021","journal-title":"Abdom Radiol"},{"key":"10.1016\/j.eururo.2025.02.020_b0440","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1016\/j.euf.2019.06.002","article-title":"The emerging role of stereotactic ablative radiotherapy for primary renal cell carcinoma: a systematic review and meta-analysis","volume":"5","author":"Correa","year":"2019","journal-title":"Eur Urol Focus"},{"key":"10.1016\/j.eururo.2025.02.020_b0445","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1016\/j.eururo.2022.06.017","article-title":"The role of stereotactic ablative body radiotherapy in renal cell carcinoma","volume":"82","author":"Ali","year":"2022","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2025.02.020_b0450","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1016\/S1470-2045(24)00020-2","article-title":"Stereotactic ablative body radiotherapy for primary kidney cancer (TROG 15.03 FASTRACK II): a non-randomised phase 2 trial","volume":"25","author":"Siva","year":"2024","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.eururo.2025.02.020_b0455","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1016\/j.radonc.2020.10.031","article-title":"Final results of a dose escalation protocol of stereotactic body radiotherapy for poor surgical candidates with localized renal cell carcinoma","volume":"155","author":"Grubb","year":"2021","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.eururo.2025.02.020_b0460","doi-asserted-by":"crossref","first-page":"204","DOI":"10.3390\/biomedicines11010204","article-title":"Current approaches in surgical and immunotherapy-based management of renal cell carcinoma with tumor thrombus","volume":"11","author":"Tabbara","year":"2023","journal-title":"Biomedicines."},{"issue":"6 Suppl","key":"10.1016\/j.eururo.2025.02.020_b0465","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1200\/JCO.2022.40.6_suppl.289","article-title":"Efficacy, safety, and biomarker analysis of neoadjuvant avelumab\/axitinib in patients (pts) with localized renal cell carcinoma (RCC) who are at high risk of relapse after nephrectomy (NeoAvAx)","volume":"40","author":"Bex","year":"2022","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eururo.2025.02.020_b0470","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/j.eururo.2021.11.022","article-title":"2021 updated European Association of Urology guidelines on the use of adjuvant pembrolizumab for renal cell carcinoma","volume":"81","author":"Bedke","year":"2022","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2025.02.020_b0475","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1016\/j.eururo.2021.04.042","article-title":"The 2021 updated European Association of Urology guidelines on renal cell carcinoma: immune checkpoint inhibitor-based combination therapies for treatment-naive metastatic clear-cell renal cell carcinoma are standard of care","volume":"80","author":"Bedke","year":"2021","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2025.02.020_b0480","doi-asserted-by":"crossref","first-page":"1359","DOI":"10.1056\/NEJMoa2312695","article-title":"Overall survival with adjuvant pembrolizumab in renal-cell carcinoma","volume":"390","author":"Choueiri","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1016\/j.eururo.2025.02.020_b0485","doi-asserted-by":"crossref","unstructured":"Bedke J, Ghanem YA, Albiges L, et al. Updated European Association of Urology guidelines on the use of adjuvant immune checkpoint inhibitors and subsequent therapy for renal cell carcinoma. Eur Urol. In press. https:\/\/doi.org\/10.1016\/j.eururo.2025.01.014.","DOI":"10.1016\/j.eururo.2025.01.014"},{"key":"10.1016\/j.eururo.2025.02.020_b0490","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/S0140-6736(23)00922-4","article-title":"Atezolizumab plus cabozantinib versus cabozantinib monotherapy for patients with renal cell carcinoma after progression with previous immune checkpoint inhibitor treatment (CONTACT-03): a multicentre, randomised, open-label, phase 3 trial","volume":"402","author":"Pal","year":"2023","journal-title":"Lancet"},{"key":"10.1016\/j.eururo.2025.02.020_b0495","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1016\/S0140-6736(24)01758-6","article-title":"Tivozanib plus nivolumab versus tivozanib monotherapy in patients with renal cell carcinoma following an immune checkpoint inhibitor: results of the phase 3 TiNivo-2 study","volume":"404","author":"Choueiri","year":"2024","journal-title":"Lancet"},{"key":"10.1016\/j.eururo.2025.02.020_b0500","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1016\/j.eururo.2018.08.008","article-title":"Updated European Association of Urology guidelines for cytoreductive nephrectomy in patients with synchronous metastatic clear-cell renal cell carcinoma","volume":"74","author":"Bex","year":"2018","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2025.02.020_b0505","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1016\/j.euo.2022.07.002","article-title":"Oncological outcomes of delayed nephrectomy after optimal response to immune checkpoint inhibitors for metastatic renal cell carcinoma","volume":"5","author":"Pignot","year":"2022","journal-title":"Eur Urol Oncol"},{"key":"10.1016\/j.eururo.2025.02.020_b0510","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1016\/j.euo.2023.03.003","article-title":"Perioperative complications and oncologic outcomes of nephrectomy following immune checkpoint inhibitor therapy: a multicenter collaborative study","volume":"6","author":"Yip","year":"2023","journal-title":"Eur Urol Oncol"},{"key":"10.1016\/j.eururo.2025.02.020_b0515","doi-asserted-by":"crossref","first-page":"1703","DOI":"10.1016\/j.euf.2021.10.004","article-title":"Outcomes of cytoreductive nephrectomy for patients with metastatic renal cell carcinoma: real world data from Canadian centers","volume":"8","author":"Dragomir","year":"2022","journal-title":"Eur Urol Focus"},{"key":"10.1016\/j.eururo.2025.02.020_b0520","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1186\/s12885-024-11987-3","article-title":"Multicenter randomized trial of deferred cytoreductive nephrectomy in synchronous metastatic renal cell carcinoma receiving checkpoint inhibitors: the NORDIC-SUN-Trial","volume":"24","author":"Iisager","year":"2024","journal-title":"BMC Cancer"},{"key":"10.1016\/j.eururo.2025.02.020_b0525","doi-asserted-by":"crossref","first-page":"2204","DOI":"10.1002\/cncr.33494","article-title":"Active surveillance of metastatic renal cell carcinoma: results from a prospective observational study (MaRCC)","volume":"127","author":"Harrison","year":"2021","journal-title":"Cancer"},{"key":"10.1016\/j.eururo.2025.02.020_b0530","doi-asserted-by":"crossref","first-page":"e549","DOI":"10.1016\/S1470-2045(14)70235-9","article-title":"Local treatments for metastases of renal cell carcinoma: a systematic review","volume":"15","author":"Dabestani","year":"2014","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.eururo.2025.02.020_b0535","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1016\/j.eururo.2017.11.016","article-title":"Updated European Association of Urology guidelines: recommendations for the treatment of first-line metastatic clear cell renal cancer","volume":"73","author":"Powles","year":"2018","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2025.02.020_b0540","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1016\/j.euo.2019.05.007","article-title":"Stereotactic ablative radiation therapy for oligometastatic renal cell carcinoma (SABR ORCA): a meta-analysis of 28 studies","volume":"2","author":"Zaorsky","year":"2019","journal-title":"Eur Urol Oncol"},{"key":"10.1016\/j.eururo.2025.02.020_b0545","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1016\/j.euf.2022.08.016","article-title":"The emerging role of extracranial stereotactic ablative radiotherapy for metastatic renal cell carcinoma: a systematic review","volume":"9","author":"Le Guevelou","year":"2023","journal-title":"Eur Urol Focus"},{"key":"10.1016\/j.eururo.2025.02.020_b0550","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1016\/S1470-2045(22)00487-9","article-title":"Pembrolizumab versus placebo as post-nephrectomy adjuvant therapy for clear cell renal cell carcinoma (KEYNOTE-564): 30-month follow-up analysis of a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial","volume":"23","author":"Powles","year":"2022","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.eururo.2025.02.020_b0555","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1056\/NEJMoa2106391","article-title":"Adjuvant pembrolizumab after nephrectomy in renal-cell carcinoma","volume":"385","author":"Choueiri","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.eururo.2025.02.020_b0560","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1200\/JCO.2002.20.1.289","article-title":"Interferon-alfa as a comparative treatment for clinical trials of new therapies against advanced renal cell carcinoma","volume":"20","author":"Motzer","year":"2002","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eururo.2025.02.020_b0565","doi-asserted-by":"crossref","first-page":"5794","DOI":"10.1200\/JCO.2008.21.4809","article-title":"Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted agents: results from a large, multicenter study","volume":"27","author":"Heng","year":"2009","journal-title":"J Clin Oncol"},{"issue":"15 Suppl","key":"10.1016\/j.eururo.2025.02.020_b0570","doi-asserted-by":"crossref","first-page":"4502","DOI":"10.1200\/JCO.2019.37.15_suppl.4502","article-title":"Randomized, double-blind phase III study of pazopanib versus placebo in patients with metastatic renal cell carcinoma who have no evidence of disease following metastasectomy: a trial of the ECOG-ACRIN cancer research group (E2810)","volume":"37","author":"Appleman","year":"2019","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eururo.2025.02.020_b0575","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1016\/j.euo.2019.08.011","article-title":"Sorafenib versus observation following radical metastasectomy for clear-cell renal cell carcinoma: results from the phase 2 randomized open-label RESORT study","volume":"2","author":"Procopio","year":"2019","journal-title":"Eur Urol Oncol"},{"key":"10.1016\/j.eururo.2025.02.020_b0580","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1016\/S1470-2045(14)71222-7","article-title":"The International Metastatic Renal Cell Carcinoma Database Consortium model as a prognostic tool in patients with metastatic renal cell carcinoma previously treated with first-line targeted therapy: a population-based study","volume":"16","author":"Ko","year":"2015","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.eururo.2025.02.020_b0585","doi-asserted-by":"crossref","first-page":"1767","DOI":"10.1056\/NEJMoa2212851","article-title":"Cabozantinib plus nivolumab and ipilimumab in renal-cell carcinoma","volume":"388","author":"Choueiri","year":"2023","journal-title":"N Engl J Med"},{"issue":"5 Suppl","key":"10.1016\/j.eururo.2025.02.020_b0590","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1200\/JCO.2025.43.5_suppl.438","article-title":"Cabozantinib (C) in combination with nivolumab (N) and ipilimumab (I) in previously untreated advanced renal cell carcinoma (aRCC): final results of COSMIC-313","volume":"44","author":"Albiges","year":"2025","journal-title":"J Clin Oncol"},{"issue":"4 Suppl","key":"10.1016\/j.eururo.2025.02.020_b0595","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1200\/JCO.2024.42.4_suppl.363","article-title":"Nivolumab plus ipilimumab (NIVO+IPI) vs sunitinib (SUN) for first-line treatment of advanced renal cell carcinoma (aRCC): long-term follow-up data from the phase 3 CheckMate 214 trial","volume":"42","author":"Tannir","year":"2024","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eururo.2025.02.020_b0600","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.ejca.2018.11.031","article-title":"Second-line targeted therapies after nivolumab-ipilimumab failure in metastatic renal cell carcinoma","volume":"108","author":"Auvray","year":"2019","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.eururo.2025.02.020_b0605","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1093\/oncolo\/oyad348","article-title":"Long-term survival in patients with relapsed\/refractory advanced renal cell carcinoma treated with tivozanib: analysis of the phase III TIVO-3 trial","volume":"29","author":"Beckermann","year":"2024","journal-title":"Oncologist"},{"key":"10.1016\/j.eururo.2025.02.020_b0610","doi-asserted-by":"crossref","first-page":"1803","DOI":"10.1056\/NEJMoa1510665","article-title":"Nivolumab versus everolimus in advanced renal-cell carcinoma","volume":"373","author":"Motzer","year":"2015","journal-title":"N Engl J Med"},{"issue":"15 Suppl","key":"10.1016\/j.eururo.2025.02.020_b0615","doi-asserted-by":"crossref","first-page":"4517","DOI":"10.1200\/JCO.2018.36.15_suppl.4517","article-title":"Prospective phase II multi-center study of individualized axitinib (Axi) titration for metastatic renal cell carcinoma (mRCC) after treatment with PD-1\/PD-L1 inhibitors","volume":"36","author":"Ornstein","year":"2018","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eururo.2025.02.020_b0620","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1056\/NEJMoa2313906","article-title":"Belzutifan versus everolimus for advanced renal-cell carcinoma","volume":"391","author":"Choueiri","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1016\/j.eururo.2025.02.020_b0625","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1016\/S0140-6736(21)00152-5","article-title":"A comparison of sunitinib with cabozantinib, crizotinib, and savolitinib for treatment of advanced papillary renal cell carcinoma: a randomised, open-label, phase 2 trial","volume":"397","author":"Pal","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.eururo.2025.02.020_b0630","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1016\/S1470-2045(23)00276-0","article-title":"Pembrolizumab plus lenvatinib as first-line therapy for advanced non-clear-cell renal cell carcinoma (KEYNOTE-B61): a single-arm, multicentre, phase 2 trial","volume":"24","author":"Albiges","year":"2023","journal-title":"Lancet Oncol"},{"issue":"16 Suppl","key":"10.1016\/j.eururo.2025.02.020_b0635","doi-asserted-by":"crossref","first-page":"4518","DOI":"10.1200\/JCO.2023.41.16_suppl.4518","article-title":"First-line lenvatinib + pembrolizumab treatment across non-clear cell renal cell carcinomas: results of the phase 2 KEYNOTE-B61 study","volume":"41","author":"Lee","year":"2023","journal-title":"J Clin Oncol"},{"issue":"16 Suppl","key":"10.1016\/j.eururo.2025.02.020_b0640","doi-asserted-by":"crossref","first-page":"4537","DOI":"10.1200\/JCO.2023.41.16_suppl.4537","article-title":"Nivolumab plus cabozantinib in patients with non-clear cell renal cell carcinoma: updated results from a phase 2 trial","volume":"41","author":"Lee","year":"2023","journal-title":"J Clin Oncol"},{"issue":"Suppl 2","key":"10.1016\/j.eururo.2025.02.020_b0645","doi-asserted-by":"crossref","first-page":"S1263","DOI":"10.1016\/j.annonc.2024.08.2318","article-title":"LBA75\u2003Prospective randomised phase-II trial of ipilimumab\/nivolumab versus standard of care in non-clear cell renal cell cancer: results of the SUNNIFORECAST trial","volume":"35","author":"Bergmann","year":"2024","journal-title":"Ann Oncol"},{"key":"10.1016\/j.eururo.2025.02.020_b0650","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1200\/JCO.2013.50.8192","article-title":"Defining early-onset kidney cancer: implications for germline and somatic mutation testing and clinical management","volume":"32","author":"Shuch","year":"2014","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eururo.2025.02.020_b0655","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1038\/nrurol.2014.162","article-title":"Molecular genetics and cellular features of TFE3 and TFEB fusion kidney cancers","volume":"11","author":"Kauffman","year":"2014","journal-title":"Nat Rev Urol"},{"key":"10.1016\/j.eururo.2025.02.020_b0660","unstructured":"Eble JN, Sauter G, Epstein J, Sesterhenn I, editors. Pathology and genetics of tumours of the urinary system and male genital organs. World Health Organization classification of tumours, volume 7. Lyon, France: International Agency for Research on Cancer; 2004."},{"key":"10.1016\/j.eururo.2025.02.020_b0665","doi-asserted-by":"crossref","first-page":"1469","DOI":"10.1097\/PAS.0b013e318299f2d1","article-title":"The International Society of Urological Pathology (ISUP) Vancouver classification of renal neoplasia","volume":"37","author":"Srigley","year":"2013","journal-title":"Am J Surg Pathol"},{"key":"10.1016\/j.eururo.2025.02.020_b0670","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1016\/j.urology.2006.09.052","article-title":"Survival analysis of 130 patients with papillary renal cell carcinoma: prognostic utility of type 1 and type 2 subclassification","volume":"69","author":"Pignot","year":"2007","journal-title":"Urology"},{"key":"10.1016\/j.eururo.2025.02.020_b0675","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1097\/PAP.0b013e318299b7c6","article-title":"Hereditary syndromes with associated renal neoplasia: a practical guide to histologic recognition in renal tumor resection specimens","volume":"20","author":"Przybycin","year":"2013","journal-title":"Adv Anatom Pathol"},{"key":"10.1016\/j.eururo.2025.02.020_b0680","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1053\/j.semdp.2018.01.005","article-title":"Morphological clues to the appropriate recognition of hereditary renal neoplasms","volume":"35","author":"Moch","year":"2018","journal-title":"Semin Diagn Pathol"},{"key":"10.1016\/j.eururo.2025.02.020_b0685","doi-asserted-by":"crossref","first-page":"2036","DOI":"10.1056\/NEJMoa2103425","article-title":"Belzutifan for renal cell carcinoma in von Hippel-Lindau disease","volume":"385","author":"Jonasch","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.eururo.2025.02.020_b0690","first-page":"14","article-title":"Increased use of cross-sectional imaging for follow-up does not improve post-recurrence survival of surgically treated initially localized R.C.C.: results from a European multicenter database (R.E.C.U.R.). Scand","volume":"53","author":"Dabestani","year":"2019","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2025.02.020_b0695","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/j.euo.2019.02.006","article-title":"Hypertension and Cardiovascular Morbidity Following Surgery for Kidney Cancer","volume":"3","author":"Capitanio","year":"2020","journal-title":"Eur Urol Oncol"}],"container-title":["European Urology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0302283825001393?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0302283825001393?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,5,28]],"date-time":"2025-05-28T10:40:42Z","timestamp":1748428842000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0302283825001393"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6]]},"references-count":139,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025,6]]}},"alternative-id":["S0302283825001393"],"URL":"https:\/\/doi.org\/10.1016\/j.eururo.2025.02.020","relation":{"is-referenced-by":[{"id-type":"doi","id":"10.1007\/s00261-026-05578-y","asserted-by":"object"}]},"ISSN":["0302-2838"],"issn-type":[{"value":"0302-2838","type":"print"}],"subject":[],"published":{"date-parts":[[2025,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"European Association of Urology Guidelines on Renal Cell Carcinoma: The 2025 Update","name":"articletitle","label":"Article Title"},{"value":"European Urology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.eururo.2025.02.020","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 European Association of Urology. Published by Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}